Study:
Evaluation of CHOP Plus Involved Field Radiotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized, Aggressive Histologies of Non-Hodgkin Lymphoma, Phase II
Rationale:
Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine,
and prednisone, use different ways to stop cancer cells from dividing so they stop growing
or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Monoclonal
antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can locate cancer cells
and either kill them or deliver radioactive cancer-killing substances to them without
harming normal cells. Combining chemotherapy with radiation therapy and monoclonal antibody
therapy may kill more cancer cells.
Purpose:
This phase II trial is studying how well giving combination chemotherapy together
with radiation therapy and monoclonal antibody therapy works in treating patients with stage
I or stage II non-Hodgkin`s lymphoma.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lymphoma |
Biological: rituximab
Drug: Cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Radiation: radiation therapy
Biological: Yttrium-90 ibritumomab tiuxetan
Biological: Indium-111 ibritumomab tiuxetan |
Phase 2 |
Verified by
Southwest Oncology Group
March, 2012
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00070018
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States
Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States
Thomas P. Miller, MD., Study Chair
Oliver W. Press, MD, PhD., Study Chair
Baldassarre D. Stea, MD, PhD., Study Chair
Louis S. Constine, MD., Study Chair